Pharmaceutical industry – Page 39
-
Business
Hikma boosts generics with Roxane buyout
Acquiring the Boehringer Ingelheim subsidiary expands Hikma’s presence in US generics market
-
Business
Allergan steps away from generics with sale to Teva
$40.5 billion deal gives Allergan cash to clear debt and fund further acquisitions, and catapults Teva into global pharma top 10
-
Business
Biogen to develop gene therapies with AGTC
$1bn deal gives Biogen rights to one clinical candidate and several earlier-stage programmes for rare eye diseases
-
BusinessChemical firms seek better grasp of biomanufacturing
The search is on for better alternatives to the ‘broken’ way companies harness compound-making organisms
-
Business
US import ban imposed on Indian pharma firm
Concerns over manufacturing processes at Emcure facility prompts Food and Drug Administration to block drug shipments
-
Business
Celgene backs immunotherapy with Juno collaboration
$1bn investment in 10-year CAR-T cell partnership for cancer treatments
-
FeaturePharma queues up for checkpoint inhibitor collaborations
Combinations of different firms’ drugs seek to reap immuno-oncology’s benefits
-
Business
Job cuts at Allergan and Transgene
Allergan is shedding 300 staff at former Actavis site in Iceland, while Transgene is closing its French manufacturing plant with loss of 120 jobs
-
Business
Allergan to buy Kythera Biopharma for $2.1bn
Acquisition strengthens firm’s position in cosmetic treatments with only drug approved for a ‘double chin’
-
OpinionMissing the target
There are plenty of things that small molecule drugs can’t touch, says Derek Lowe, and it’s not for want of trying
-
Business
Alnylam accuses Dicerna of stealing trade secrets
Firm claims rights to GalNAc conjugated siRNA technology acquired from Merck & Co
-
Business
Suspect suicide won’t end trade secret theft probe
An ex-PPG chemist who was arrested for selling trade secrets to a Chinese firm has killed himself, but the Justice Department will continue its investigation
-
BusinessCompanies clamour for CAR-T
Engineered immune cell therapies show promise in early cancer trials, prompting firms to compete for a foothold in the field
-
Business
Vertex nabs rights to cystic fibrosis molecules
Deal with Parion, worth up to $1bn, gives firm worldwide rights to investigational treatments that complement Vertex’s existing cystic fibrosis drugs
-
Business
Opko deepens diagnostics with $1.5bn lab buyout
Taking over clinical diagnostics service provider BioReference Laboratories gives Opko a bigger avenue to distribute and market its diagnostic tests
-
BusinessBMS sues executive for joining rival company
Bristol-Myers Squibb’s lawsuit against its former immuno-oncology chief who left to work for AstraZeneca has implications for biopharma industry
-
Business
Takeda to consolidate vaccines business in Boston
Firm will close three recently-acquired US sites and shift operations to the growing pharmaceutical hub in Massachusetts
-
Business
Teva fined $1.2bn in pay-for-delay case
Company illegally blocked generic competition of sleep disorder drug, and settlement terms tighten up rules on anticompetitive behaviour
-
Business
Achillion partners with Janssen to boost hepatitis C pipeline
Development deal worth up to $1.1bn includes three investigational drugs aiming to extend treatment options in fast-moving market